A recent meta-analysis report of 8 trials reporting on 77,242 patients enrolled in GLP1R agonists and SGLT2 inhibitor trials in which the primary outcomes were the composite of myocardial infarction, stroke, and MACE and hospitalization for heart failure, and progression of kidney disease concluded that both therapeutic strategies were equally effective in reducing MACE in patients that had established CVD [75••]. This evidence concerns the gene SLC5A2 and heart failure.